Liberty Francois-Moutal

List of Publications by Year
in descending order

21	666	623734 14	713466 21
papers	citations	h-index	g-index

24	24	24	633
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Structural Insights Into TDP-43 and Effects of Post-translational Modifications. Frontiers in Molecular Neuroscience, 2019, 12, 301.	2.9	86
2	A membrane-delimited N-myristoylated CRMP2 peptide aptamer inhibits CaV2.2 trafficking and reverses inflammatory and postoperative pain behaviors. Pain, 2015, 156, 1247-1264.	4.2	71
3	CRISPR/Cas9 editing of Nf1 gene identifies CRMP2 as a therapeutic target in neurofibromatosis type 1-related pain that is reversed by (S)-Lacosamide. Pain, 2017, 158, 2301-2319.	4.2	67
4	(S)-Lacosamide Binding to Collapsin Response Mediator Protein 2 (CRMP2) Regulates CaV2.2 Activity by Subverting Its Phosphorylation by Cdk5. Molecular Neurobiology, 2016, 53, 1959-1976.	4.0	50
5	Inhibition of the Ubc9 E2 SUMO-conjugating enzymeâ€“CRMP2 interaction decreases NaV1.7 currents and reverses experimental neuropathic pain. Pain, 2018, 159, 2115-2127.	4.2	49
6	Small Molecule Targeting TDP-43â€™s RNA Recognition Motifs Reduces Locomotor Defects in a Drosophila Model of Amyotrophic Lateral Sclerosis (ALS). ACS Chemical Biology, 2019, 14, 2006-2013.	3.4	45
7	Homologyâ€guided mutational analysis reveals the functional requirements for antinociceptive specificity of collapsin response mediator protein 2â€derived peptides. British Journal of Pharmacology, 2018, 175, 2244-2260.	5.4	40
8	The functionalized amino acid (S)-Lacosamide subverts CRMP2-mediated tubulin polymerization to prevent constitutive and activity-dependent increase in neurite outgrowth. Frontiers in Cellular Neuroscience, 2014, 8, 196.	3.7	38
9	Differential neuroprotective potential of CRMP2 peptide aptamers conjugated to cationic, hydrophobic, and amphipathic cell penetrating peptides. Frontiers in Cellular Neuroscience, 2015, 8, 471.	3.7	37
10	A single structurally conserved SUMOylation site in CRMP2 controls NaV1.7 function. Channels, 2017, 11, 316-328.	2.8	34
11	Targeting the CaVÎ±â€“CaVÎ² interaction yields an antagonist of the N-type CaV2.2 channel with broad antinociceptive efficacy. Pain, 2019, 160, 1644-1661.	4.2	30
12	Selective targeting of NaV1.7 via inhibition of the CRMP2-Ubc9 interaction reduces pain in rodents. Science Translational Medicine, 2021, 13, eabh1314.	12.4	23
13	The Natural Flavonoid Naringenin Elicits Analgesia through Inhibition of NaV1.8 Voltage-Gated Sodium Channels. ACS Chemical Neuroscience, 2019, 10, 4834-4846.	3.5	20
14	An Allosteric Modulator of RNA Binding Targeting the N-Terminal Domain of TDP-43 Yields Neuroprotective Properties. ACS Chemical Biology, 2020, 15, 2854-2859.	3.4	19
15	Chemical shift perturbation mapping of the Ubc9-CRMP2 interface identifies a pocket in CRMP2 amenable for allosteric modulation of Nav1.7 channels. Channels, 2018, 12, 219-227.	2.8	17
16	Heat shock protein Grp78/BiP/HspA5 binds directly to TDP-43 and mitigates toxicity associated with disease pathology. Scientific Reports, 2022, 12, 8140.	3.3	12
17	In Silico Targeting of the Long Noncoding RNA MALAT1. ACS Medicinal Chemistry Letters, 2021, 12, 915-921.	2.8	10
18	A Chemical Biology Approach to Model Pontocerebellar Hypoplasia Type 1B (PCH1B). ACS Chemical Biology, 2018, 13, 3000-3010.	3.4	9

#	Article	IF	Citations
19	1H, 15N and 13C backbone assignment of apo TDP-43 RNA recognition motifs. Biomolecular NMR Assignments, 2019, 13, 163-167.	0.8	3
20	Evaluation of edonerpic maleate as a CRMP2 inhibitor for pain relief. Channels, 2019, 13, 498-504.	2.8	2
21	Remodeling the interactions between TDP43 and RNA for development of therapeutics for ALS. FASEB Journal, 2019, 33, 670.1.	0.5	0